Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Saved in:
| Title: | Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. |
|---|---|
| Authors: | Feldman SR; Wake Forest School of Medicine, Winston-Salem, NC, USA., Merola JF; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Pariser DM; Eastern Virginia Medical School, Virginia Clinical Research, Inc, Norfolk, VA, USA., Zhang J; Sun Pharmaceutical Industries Inc., Princeton, NJ, USA., Zhao Y; Sun Pharmaceutical Industries Inc., Princeton, NJ, USA., Mendelsohn AM; Sun Pharmaceutical Industries Inc., Princeton, NJ, USA., Gottlieb AB; Icahn School of Medicine at Mount Sinai, New York, NY, USA. |
| Source: | The Journal of dermatological treatment [J Dermatolog Treat] 2022 May; Vol. 33 (3), pp. 1670-1675. Date of Electronic Publication: 2021 Mar 18. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-1753 |
|---|---|
| DOI: | 10.1080/09546634.2021.1898528 |
